A5042879900- Mechanical Circulatory Support Devices
- Cardiac Structural Anomalies and Repair
- Heart Failure Treatment and Management
- Pulmonary Hypertension Research and Treatments
- Cardiac pacing and defibrillation studies
- Transplantation: Methods and Outcomes
- Cardiac Arrest and Resuscitation
- Cardiovascular Function and Risk Factors
- Renal Transplantation Outcomes and Treatments
- Cardiovascular Issues in Pregnancy
- Atrial Fibrillation Management and Outcomes
- Hepatitis C virus research
- Viral Infections and Immunology Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Venous Thromboembolism Diagnosis and Management
- Cardiac Arrhythmias and Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Diabetes Treatment and Management
- Congenital Heart Disease Studies
- Family and Patient Care in Intensive Care Units
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Pericarditis and Cardiac Tamponade
- Complement system in diseases
- Cardiac electrophysiology and arrhythmias
- Fuel Cells and Related Materials
St. Vincent Hospital
2015-2025
St Vincent Hospital
2015-2024
JSS Academy of Higher Education and Research
2024
Saint Vincent's Catholic Medical Center
2021-2023
Ascension
2023
Icahn School of Medicine at Mount Sinai
2023
St. Vincent's Birmingham
2023
Saint Vincent Health System
2018-2021
St Vincent Medical Center
2017-2021
Advocate Christ Medical Center
2017
No therapies are currently approved for the treatment of pulmonary hypertension in patients with interstitial lung disease. The safety and efficacy inhaled treprostinil this condition unclear.We enrolled disease (documented by right heart catheterization) a multicenter, randomized, double-blind, placebo-controlled, 16-week trial. Patients were assigned 1:1 ratio to receive treprostinil, administered means an ultrasonic, pulsed-delivery nebulizer up 12 breaths (total, 72 μg) four times daily,...
<h3>Importance</h3> The use of sacubitril/valsartan is not endorsed by practice guidelines for in patients with New York Heart Association class IV heart failure a reduced ejection fraction because limited clinical experience this population. <h3>Objective</h3> To compare treatment valsartan advanced and recent symptoms. <h3>Design, Setting, Participants</h3> A double-blind randomized trial was conducted; total 335 were included. began on March 2, 2017, stopped early 23, 2020, owing to...
<h3>Importance</h3> Left ventricular assist devices (LVADs) are well established in the treatment of advanced heart failure, but it is unclear whether outcomes different based on intended goal therapy patients who eligible vs ineligible for transplant. <h3>Objective</h3> To determine clinical Multicenter Study MagLev Technology Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) trial differed by preoperative categories bridge to transplant (BTT) or...
Recently, a percutaneous right ventricular assist device (RVAD) called the TandemLife Protek Duo (TPD; TandemLife, Pittsburgh, PA) has been introduced. The (TPD) is temporary RVAD placed via internal jugular vein, capable of providing up to 4.5 L flow. We report two-center experience using TPD in 17 patients with (RV) failure, 12 whom were post-left (LVAD) implantation.
Introduction The 16-week randomised, placebo-controlled INCREASE trial (RCT) met its primary end-point by improving 6-min walk distance (6MWD) in patients receiving inhaled treprostinil for pulmonary hypertension due to interstitial lung disease (PH-ILD). open-label extension (OLE) evaluated long-term effects of PH-ILD. Methods Of 258 eligible patients, 242 enrolled the OLE and received treprostinil. Assessments included 6MWD, function testing, N-terminal pro-brain natriuretic peptide...
BackgroundMolecular testing with gene expression profiling (GEP) and donor-derived cell-free DNA (dd-cfDNA) is increasingly used in the surveillance for acute cellular rejection (ACR) after heart transplant. However, performance of dual over each test individually has not been established. Further, impact non-invasive on clinical decision-making widely investigated.MethodsWe evaluated 2077 subjects from SHORE registry who were enrolled between 2018 2021 had verified biopsy data, categorized...
Biosurfactants are surface active agents produced by microorganisms, which help reduce or interfacial tension between two immiscible liquids like oil and water. In recent years, Due to their environmentally friendly nature wide range of applications in various industries, they can act as a sustainable alternative synthetic surfactants. This review article provides an overview biosurfactants, emphasizing need for the production process, classification based on molecular weight, charge,...
Introduction: The safe and efficient Intravenous (i.v.) administration of Tranexamic Acid (TXA) has been shown to reduce blood loss transfusion requirements following total hip replacement. However, its effectiveness in arthroplasty for femoral neck fractures remains a subject debate date. Aim: To evaluate the effects TXA patients undergoing prevent loss. Materials Methods: present prospective, doubleblinded, randomised controlled study was conducted Department Orthopaedics, SRM Medical...
Background: Cisplatin is the most common chemotherapeutic drug which used concurrently with radiation therapy due to its radio sensitizing effect. known cause substantial amount of nephrotoxicity and adequate hydration absolutely essential while administering cisplatin. Once weekly regimen widely both in treatment head & neck cancers as well cervical cancer. The main aim this study compare incidence severity patients cancer treated concurrent chemoradiation Methods: From January 2023...
Many patients with heart failure continue cardiac resynchronization therapy (CRT) after continuous flow left ventricular assist device (CF-LVAD) implant. We report the first multicenter study to assess impact of CRT on clinical outcomes in CF-LVAD patients.
Background: The coronavirus disease 2019 (COVID-19) pandemic continues to afflict millions of people worldwide. Patients with end-stage heart failure and left ventricular assist devices (LVADs) may be at risk for severe COVID-19 given a high prevalence complex comorbidities functional impaired immunity. objective this study is describe the clinical characteristics outcomes in patients durable LVADs. Methods: Trans-CoV-VAD registry multi-center LVAD cardiac transplant United States confirmed...
Summary Introduction Secondary pulmonary hypertension ( PH ) and right ventricular dysfunction are common associated with poor prognosis in HF patients left assist devices LVAD s). The role of vasodilator therapy for these is currently unclear. Aims We sought to evaluate the safety clinical course treated bosentan, an endothelin receptor antagonist, after implementation a . Results Between 10/2008 5/2011, 50 consecutive mean PAP >25 mmHg were bosentan implantation duration 15.7 (±12.4)...